Trial · NCT04591990
HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome
NCT04591990, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome. Trials, record NCT04591990. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04591990
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome
- NCT number
- NCT04591990
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 380 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Postresuscitation Syndrome
- Interventions
- Administration of AVP, Administration of placebo AVP, Administration of placebo hydrocortisone, Administration of hydrocortisone
- First posted
- 2020-10-19
- Last updated
- 2025-06-12
- Other registries' IDs
- eudract:2020-001620-33
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Neurological outcome | at day-30 | The primary endpoint will be the good neurological outcome at day-30. This will be evaluated using the Glasgow Outcome Scale (GOS, addendum 18.5.1) dichotomized as follow: good neurological outcome for categories 4 and 5 and poor neurological outcome or death for categories 3, 2 and 1. The GOS will be obtained at day-30 from an in-hospital visit if the patient is still hospitalized or from telephone contact with patients, relatives or general practitioners. |
| Secondary | All-cause mortality | at day-30 | Vital status at day-30. |
| Secondary | Mortality attributed to irreversible hemodynamic failure | at day-30 | Time to irreversible cardiovascular failure defined as death in pharmacologically uncontrollable hypotension (mean arterial blood pressure \< 60 mmHg) despite maximal ICU care, or withdrawal of care based on same, as previously defined (Witten L, Resuscitation 2019). |
| Secondary | Mortality attributed to neurological withdrawal of care | at day-30 | Time to neurological withdrawal of care. Withdrawal of care will be based on expectations of a poor neurological recovery based on most recent guidelines (Sandroni C, ICM 2015). |
| Secondary | Mortality attributed to comorbid withdrawal of care | at day-30 | Time to comorbid withdrawal of care. Comorbid withdrawal of care or refusal of life-sustaining therapy based on the expectation of a poor quality of life. This may be related to a preexisting or newly discovered terminal illness or other serious medical condition (e.g. dementia or cancer). |
| Secondary | Day-30 brain death | at day-30 | Time to brain death (according to French legislation) |
| Secondary | mortality attributed to recurrent cardiac arrest | at day-30 | Time to recurrent cardiac arrest |
| Secondary | Other causes | at day-30 | Proportion of patients dead from a cause not listed above. |
| Secondary | Neurological recovery at day-30 | at day-30 | Glasgow outcome score - extended at day-30. This score will be evaluated similarly to the primary endpoint |
| Secondary | Brain damage | at 48 hours and at 72hours | Neuron-specific enolase (NSE) blood level measured 48 and 72 hours after CA |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04591990
GET https://conductscience.org/api/trials/v1/NCT04591990/registered